[HTML][HTML] Disease-modifying therapies and infectious risks in multiple sclerosis
A Winkelmann, M Loebermann, EC Reisinger… - Nature Reviews …, 2016 - nature.com
Immunomodulatory and immunosuppressive treatments for multiple sclerosis (MS) are
associated with an increased risk of infection, which makes treatment of this condition …
associated with an increased risk of infection, which makes treatment of this condition …
The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy
Y Gilgun-Sherki, E Melamed, D Offen - Journal of neurology, 2004 - Springer
Accumulating data indicate that oxidative stress (OS) plays a major role in the pathogenesis
of multiple sclerosis (MS). Reactive oxygen species (ROS), leading to OS, generated in …
of multiple sclerosis (MS). Reactive oxygen species (ROS), leading to OS, generated in …
[图书][B] Statistik: Lehr-und Handbuch der angewandten Statistik
J Hartung - 2009 - degruyter.com
(J Vereinigung überj:(J Aj= Aj u... υ An. i if ι η Ρ) Durchschnitt über j: Aj= At η... η An. ij= iz= a+
ib komplexe Zahl ζ mit Realteil a und Imaginärteil b (a, b reelle Zahlen); i heißt hier …
ib komplexe Zahl ζ mit Realteil a und Imaginärteil b (a, b reelle Zahlen); i heißt hier …
[图书][B] Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine
DB Petitti - 2000 - books.google.com
Meta-analysis, decision analysis, and cost-effectiveness analysis are the cornerstones of
evidence-based medicine. These related quantitative methods have become essential tools …
evidence-based medicine. These related quantitative methods have become essential tools …
[图书][B] Survival analysis: a practical approach
D Machin, YB Cheung, M Parmar - 2006 - books.google.com
Well received in its first edition, Survival Analysis: A Practical Approach is completely revised
to provide an accessible and practical guide to survival analysis techniques in diverse …
to provide an accessible and practical guide to survival analysis techniques in diverse …
[HTML][HTML] Natural history of multiple sclerosis with childhood onset
C Renoux, S Vukusic, Y Mikaeloff, G Edan… - … England Journal of …, 2007 - Mass Medical Soc
Background The course and prognosis of childhood-onset multiple sclerosis have not been
well described. Methods We used data from 13 adult neurology departments affiliated with …
well described. Methods We used data from 13 adult neurology departments affiliated with …
The clinical pharmacology of 6-mercaptopurine
L Lennard - European journal of clinical pharmacology, 1992 - Springer
The cytotoxic drug 6-mercaptopurine (6-MR b-thiopurine) and the closely related
immunosuppressive agent azathioprine (6-(1-methyl-4-nitro-5-irnidazolylthio) purine) act as …
immunosuppressive agent azathioprine (6-(1-methyl-4-nitro-5-irnidazolylthio) purine) act as …
[HTML][HTML] Diagnosis and management of multiple sclerosis
PA Calabresi - American family physician, 2004 - aafp.org
Multiple sclerosis, an idiopathic inflammatory disease of the central nervous system, is
characterized pathologically by demyelination and subsequent axonal degeneration. The …
characterized pathologically by demyelination and subsequent axonal degeneration. The …
Animal models of multiple sclerosis—potentials and limitations
E Mix, H Meyer-Rienecker, HP Hartung… - Progress in neurobiology, 2010 - Elsevier
Experimental autoimmune encephalomyelitis (EAE) is still the most widely accepted animal
model of multiple sclerosis (MS). Different types of EAE have been developed in order to …
model of multiple sclerosis (MS). Different types of EAE have been developed in order to …
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome
E Millefiorini, C Gasperini, C Pozzilli, F D'andrea… - Journal of …, 1997 - Springer
We designed a randomized, placebo-controlled, multicentre trial involving 51 relapsing-
remitting multiple sclerosis patients to determine the clinical efficacy of mitoxantrone …
remitting multiple sclerosis patients to determine the clinical efficacy of mitoxantrone …